Stephane Bancel

This inventor holds 31 USPTO granted patents and 50 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Modified Nucleic Acids. Top assignees: Modernatx, Inc., Moderna Therapeutics, Inc.. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephane Bancel. Retrieved from https://idiyas.com/inventor/stephane-bancel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 50)

% Patents Active = 96.8

CIPO Patents = 1 (Patent Applications = 14)

EPO Patents = 9 (Patent Applications = 40)

Average Co-Inventor Count = 5.1

ph-index = 16

Forward Citations = 1,659(Granted Patents)

Location History:

Boston, MA (US) (2014 - 2016)
Cambridge, MA (US) (2015 - 2024)

Company Filing History:

Moderna Therapeutics, Inc.

patents

Years Active: 2014-2024

Loading Chart...

Areas of Expertise:

Modified Nucleic Acids

RNA Purification

Biologics Production

Terminally Modified RNA

Engineered Nucleic Acids

Oncology-Related Proteins

In Vivo Protein Production

Polynucleotides

Cosmetic Proteins

Proteins Associated with Human Disease

Nuclear Proteins

Cytoskeletal Proteins

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12023371 - Terminally modified RNA (2024-07-02),

2. 11845772 - Ribonucleic acid purification (2023-12-19),

3. 11377470 - Ribonucleic acid purification (2022-07-05),

4. 10925935 - Terminally Modified RNA (2021-02-23),

5. 10858647 - Removal of DNA fragments in mRNA production process (2020-12-08),

6. 10772975 - Modified Polynucleotides for the production of biologics and proteins associated with human disease (2020-09-15),

7. 10751386 - Engineered nucleic acids and methods of use thereof (2020-08-25),

8. 10155029 - Terminally modified RNA (2018-12-18),

9. 10138507 - Manufacturing methods for production of RNA transcripts (2018-11-27),

10. 10077439 - Removal of DNA fragments in mRNA production process (2018-09-18),

11. 10022425 - Engineered nucleic acids and methods of use thereof (2018-07-17),

12. 9937233 - Engineered nucleic acids and methods of use thereof (2018-04-10),

13. 9878056 - Modified polynucleotides for the production of cosmetic proteins and peptides (2018-01-30),

14. 9828416 - Modified polynucleotides for the production of secreted proteins (2017-11-28),

15. 9827332 - Modified polynucleotides for the production of proteins (2017-11-28),

Title: The Innovative Journey of Inventor Stephane Bancel

Introduction: Stephane Bancel is a visionary inventor based in Cambridge, MA (US) known for his groundbreaking contributions to the field of biotechnology and healthcare.

Latest Patents: Stephane Bancel holds several patents related to mRNA technology, including patents for novel drug delivery systems and therapeutic applications.

Career Highlights: With a background in biopharmaceuticals, Stephane Bancel has held key leadership positions in various biotech companies, driving innovation and spearheading research and development efforts.

Collaborations: Throughout his career, Stephane Bancel has collaborated with leading scientists, researchers, and institutions to advance the development of cutting-edge medical technologies and treatments.

Conclusion: Stephane Bancel's dedication to innovation and his relentless pursuit of scientific excellence continue to shape the landscape of modern medicine, making him a prominent figure in the world of inventors and innovators.

Profile summary based on public USPTO records.